Dabrafenib
Orphan DrugFDA Approved
Contents
Description
Dabrafenib is a kinase inhibitor indicated for the treatment of anaplastic thyroid cancer with BRAF V600E mutation. It inhibits BRAF V600E kinase, which is involved in cell signaling and growth.
Indications & Therapeutic Use
Anaplastic thyroid cancer with BRAF V600E mutation
Linked Diseases:
Global Availability (2 countries)
| Country | Access Route | Regulatory Pathway | Lead Time | Status |
|---|---|---|---|---|
| — | — | — | — | |
| — | — | — | — |
Buy / Source Dabrafenib — GNH India
18 matching products available through GNH India. Select a product to view details and request a quote on the GNH India website.
Browse all Dabrafenib products on GNH IndiaProducts and ordering are fulfilled by GNH India. You will be redirected to www.gnhindia.com.
Available Through
This drug is available for procurement through the following fulfilment partner.
Fulfilment Partner
Dabrafenib
| Generic Name | Dabrafenib |
| Brands | 1 brand available |
| Active Ingredient | Dabrafenib mesylate |
| Drug Class | Anaplastic thyroid cancer with BRAF V600E mutation |
| Manufacturer | Novartis |
| Dosage Forms | Capsule |
| Medical Code | L01EC01 |
| Orphan Status | Yes — Orphan Drug |
| Cold Chain | Not Required |
| Reg. Status | FDA Approved |
| Countries | 2 countries |
Authority Signals
Last Verified3/21/2026
Data ConfidenceHigh (AI + Pharmacist)
Source Citations3 Validated Nodes